RE:RE:Update pleaseAgree - it won't happen. That's why I have provided this guess for the shareholders dumping. Someone actually sold at $2.93 today. That's absurd if that shareholder actually knew something along the lines of that make-believe PR. You'd easily hold it knowing that in 6 weeks you will hear about a final dose that is large, safe, and ready to go. We know that, but the $2.93 seller clearly does not or they would not have sold--unless they know something we don't.
SPCEO1 wrote: This is a totally reasonable request but I do not expect TH to listen based on passed experience. It is abundantly obvious at this point that Christian has his side of the company humming along pretty nicely, and always had, but the financial side of the company has never been able to manage its affairs with the same degree of competance. Until they recognize that they need to do something different than what they have been doing, their engagement with the investment community will likely remain pretty awful. They do many things right and maded some real progress while Leah was there on basic issues but shareholders like ourselves, who have seen quite a bit over the years, know there is still something critical missing that keeps investors from embracing the company.
Wino115 wrote: Paul, throw us a bone if you do know your previous approximate deadline is moved out to post 4th quarter. Since there is no IR or PR, I have written a nice little update for you to release this afternoon after running it by counsel.
"...excited to update the market on corporate developments in light of our previous releases around reaching MTD in our Phase 1a trial. Phase 1a now proceeding on a longer time line, a time line we have always disclosed as a possibility, due to ongoing sucess in the dose escalation results such that we now have X patients at X dose, no toxicity events at this current level, and the possibility it could move up another level per protocal. If the trial continues along these lines, our clinically-derived maximum dose is set at 750mg --meaning if patients are still not at a dose limiting toxicity, we will have reached our internal maximum we have designed for TH1902. Our original expectation of a 4th quarter completion and MTD identification will likely spill over to January due to reaching these high therapeutic levels, spacing out of patient enrollment, and needing to complete the 1a trial as specified.
As our dosage trial continues to extend, we see it permitting a wide therapeutic window in which to test the full efficacy of our innovative, first-in-class SORT1 PDC in the next phase of the trial. As we continue to follow the prescribed dosage increase and safety protocal, we foresee entering into the extension trial early in the year in an advantageous position. Given our fast track access, we have been discussing our findings and how they will fully inform the structure of the extension trial. As stated in the past, the current design is for 4 cancers with 10 patients each. This could be modified based on findings and discussions and we will release information as we finalize it.
With the potential of a payload on our PDC 1.5x the maximun docetaxol chemo regime dose or higher, coupled with the fact our PDC concentrates the chemo inside the tumor at multiples of what is seen with typical docetaxol chemo treatments, we believe TH1902 will have the potential to work along the lines seen in our pre-clinical invivo work.
As a reminder, this trial is for all-comers, there is no screening for our target receptor Sortilin 1, and we have been dosing along the previously released schedule at 5 cancer centers. At the 420mg level a patient had a non-febrile neutropenia, not a dose limiting toxicity, which then required 3 more patients at that level before moving up. The study is being led by Dr. Meric-Bernstein at the MD Anderson Cancer Center in Houston TX. We look forward to updating along the timeline discussed above should our maximu tolerated dosage be achieved."